174 related articles for article (PubMed ID: 7260915)
1. Pharmacokinetics of vincristine sulfate in adult cancer patients.
Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of vincristine sulfate in children.
Sethi VS; Kimball JC
Cancer Chemother Pharmacol; 1981; 6(2):111-5. PubMed ID: 7307229
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of mitomycin C in humans.
den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans.
Jackson DV; Sethi VS; Spurr CL; McWhorter JM
Cancer Res; 1981 Apr; 41(4):1466-8. PubMed ID: 6260340
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
9. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of vindesine and vincristine in humans.
Owellen RJ; Root MA; Hains FO
Cancer Res; 1977 Aug; 37(8 Pt 1):2603-7. PubMed ID: 872088
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and bioavailability of cefquinome in healthy piglets.
Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ
J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.
Sethi VS; Surratt P; Spurr CL
Cancer Chemother Pharmacol; 1984; 12(1):31-5. PubMed ID: 6690071
[TBL] [Abstract][Full Text] [Related]
15. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
[TBL] [Abstract][Full Text] [Related]
16. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.
Sinkule JA; Hutson P; Hayes FA; Etcubanas E; Evans W
Cancer Res; 1984 Jul; 44(7):3109-13. PubMed ID: 6539169
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
